Show simple item record

dc.contributor.advisorAshton, John Clive
dc.contributor.advisorSmith, Paul
dc.contributor.advisorBunn, Stephen
dc.contributor.authorRivers Auty, Jack Rocky-Jay
dc.date.available2013-10-23T01:51:02Z
dc.date.copyright2013
dc.identifier.citationRivers Auty, J. R.-J. (2013). An investigation into the cannabinoid receptor type 2 as a therapeutic target for childhood cerebral hypoxia (Thesis, Doctor of Philosophy). University of Otago. Retrieved from http://hdl.handle.net/10523/4350en
dc.identifier.urihttp://hdl.handle.net/10523/4350
dc.description.abstractCannabis sativa is an herbaceous plant that when consumed produces a number of well-known effects on the body, primarily elicited by two G-protein coupled receptors: cannabinoid receptor type 1 (CBI) and type 2 (CBII). Activation of the CBII receptor suppresses the inflammatory response of the immune system. Research has suggested that inflammation can be pathological in central nervous system (CNS) injuries and during early development the brain may be more sensitive to inflammation. Therefore, this research aimed to assess if CBII selective agonists could be neuroprotective in an animal model of childhood cerebral hypoxia (CCH) through an anti-inflammatory mechanism. A previously established model of CCH, that involved the ligation of the left carotid artery of a P26 rat, followed by a fixed hypoxic period, was chosen because of age suitability and its applicability to both asphyxia and stroke pathologies. Investigations into the variability of infarction in the established model, lead to the development of a new model that ended following a clonic tonic seizure. This new model caused significantly less variable brain infarctions compared to the previously reported model and was named Variable hypoxia ischemia (Variable HI). Two CBII agonists were then tested for neuroprotective properties in Variable HI using a partial agonist (GW405833) and a full agonist (HU910). Both single and multiple drug administration strategies were tested and found to provide no substantial tissue protection. Furthermore, behavioral tests were performed following the multiple administration strategy and no differences were found in any functional outcome. Therefore, the anti-inflammatory effects of CBII agonists are unlikely to be substantially therapeutic following CCH. It was argued that this lack of efficacy was caused by the possibility that inflammation is not truly pathological following CCH.
dc.format.mimetypeapplication/pdf
dc.language.isoen
dc.publisherUniversity of Otago
dc.rightsAll items in OUR Archive are provided for private study and research purposes and are protected by copyright with all rights reserved unless otherwise indicated.
dc.subjectMarijuana
dc.subjectCannabinoid
dc.subjectreceptor
dc.subjectstroke
dc.subjectbrain damage
dc.subjectneuroscience
dc.subjectneuroprotection
dc.subjectinflammation
dc.subjectmicroglia
dc.subjectanimal models
dc.subjectCB2
dc.subjectpharmacology
dc.titleAn investigation into the cannabinoid receptor type 2 as a therapeutic target for childhood cerebral hypoxia
dc.typeThesis
dc.date.updated2013-10-23T01:24:39Z
dc.language.rfc3066en
thesis.degree.disciplinePharmacology and Toxicology
thesis.degree.nameDoctor of Philosophy
thesis.degree.grantorUniversity of Otago
thesis.degree.levelDoctoral
otago.openaccessOpen
 Find in your library

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record